1. South Korea Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Hugel, Inc.

Hugel, Inc.

145020.KQ
Hugel, Inc.KR flagKOSDAQ
240,500.00
KRW
+4,500.00
- -
2.60TMarket Cap
Hugel, Inc.
145020.KQ
(KOSDAQ)

Recent

price

240,500.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
7,231.23
10,233
15,103.3
19,446.54
18,259.73
5,520.5
17,100.74
19,008.93
23,636.77
28,223.95
34,389.4
39,414.3
41,288.42
Revenue per Share
2,356.72
5,336.07
5,262.59
7,777.86
6,981.5
1,203.91
3,402.68
4,733
4,811
8,217
12,520
13,061
13,801.36
Basic EPS, GAAP
679.02
1,047.09
3,532.84
6,083.75
4,912.63
1,311.91
2,360.79
3,077.59
2,987.17
6,811.03
10,669.86
11,175.55
12,205.08
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
9.35
- -
- -
- -
Dividend per Share
5,483.84
10,177.52
13,146.1
19,364.17
76,357.94
20,792.71
66,031.31
69,490.07
75,979.39
83,217.28
99,295.03
108,154.49
110,154.93
Book Value per Share
7,472.48
23,729.85
25,545.67
69,871.6
67,306.69
16,479.76
50,585.12
51,793.09
54,492.4
52,738.15
59,449.31
73,138.39
76,396.58
Tangible Book Value per Share
6
6
8
9
10
37
12
12
12
11
11
11
11
Basic Weighted Avg Shares
40,350
65,066
124,189
182,085
182,392
204,568
211,038
231,859
281,675
319,700
373,047
425,110
451,929
Sales/Revenue/Turnover
38.38
27.29
50.94
55.98
33.21
33.28
36.99
41.24
35.99
36.84
44.56
47.25
46.36
Operating Margin (%)
608
1,550
4,809
6,762
7,491
9,486
10,704
14,299
13,994
13,860
15,036
19,746
21,103
Depreciation Expense
13,150
33,929
43,273
72,827
69,736
44,612
41,992
57,730
57,332
93,076
135,814
140,872
151,065
Net Income, GAAP
15.79
8.79
20.88
21.44
23.98
27.89
34.64
32.33
12.56
26.72
13.35
25.3
26.01
Effective Tax Rate (%)
32.59
52.15
34.84
40
38.23
21.81
19.9
24.9
20.35
29.11
36.41
33.14
33.43
Profit Margin (%)
-2,023
89,626
131,437
656,714
661,763
603,343
624,635
562,054
440,550
510,347
461,846
586,318
627,424
Working Capital
- -
- -
- -
79,572
82,926
89,999
92,322
96,819
1,259
89,915
34,842
751
548
LT Debt
42,674
215,191
273,940
717,920
784,783
744,271
794,069
829,168
849,454
779,678
840,812
980,162
1,034,684
Total Equity
- -
11.16
19.93
14.7
5.51
5.77
5.92
7.15
9.33
9.23
15.98
15.35
15.11
Return on Invested Capital (%)
- -
48.71
35.12
31.74
11.19
4.59
4.41
5.89
5.5
8.52
11.68
11.41
11.9
Return on Capital (%)
- -
71.2
50.08
50.33
14.77
5.82
5.3
6.95
6.54
10.07
13.45
12.56
13.05
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
25,404
28,377
28,012
LT Borrowings
- -
- -
- -
LT Finance Leases
8,817
751
548
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
11
11
11
Market Capitalization
3,301,194
2,519,620
2,632,429

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
616,560
679,367
724,029
Cash, Cash Equivalents & STI
478,032
538,772
584,656
Accounts Receivable, Net
75,700
74,989
74,339
Inventories
52,081
55,845
55,041
Total Current Liabilities
83,086
93,049
96,605
Payables & Accruals
- -
- -
- -
ST Debt
25,404
28,377
28,012
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
22.33%
4.61%
16.57%
Free Cash Flow
57.21%
38.91%
4.14%
Net Income, GAAP
19.85%
29.76%
3.72%
Sales/Revenue/Turnover
22.85%
15.1%
13.96%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
74,306
95,423
105,109
98,209
373,047
2025
89,820
110,260
105,898
119,131
425,110
2026
116,639
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,923
3,272
3,667
- -
12,520
2025
2,701
3,331.49
3,316.67
- -
13,061
2026
3,633.6
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Monte Rosa Therapeutics, Inc. (GLUE)
Sarepta Therapeutics, Inc. (0L35.L)
Veraxa Biotech Holding AG (VRXA)
Medesis Pharma S.A. (ALMDP.PA)
Pluri Inc. (PLUR)
D&D Pharmatech (347850.KQ)
Business
Hugel, Inc. develops and manufactures biopharmaceuticals focused on medical aesthetics in South Korea and internationally; the company produces botulinum toxin products under the Botulax, Regenox, Zentox, Reage, Magnion, Hugel Toxin, Juvenlife, Botulim, Botoshot, and Letybo brands for treatments including eyelid convulsion, glabellar lines, upper limb spasticity, equinus foot deformity, and crow's feet; hyaluronic acid fillers under the Dermalax and The Chaeum brand names; skin boosters and cosmetics under the Wellage brand; and medical devices including lifting threads and products under the BlueRose brand. Hugel operates manufacturing facilities in Chuncheon-si and Seoul, South Korea, with a presence in approximately 70 countries through eight global subsidiaries in the US, Australia, Canada, Taiwan, China, Hong Kong, and Singapore; it targets medical professionals and consumers in the aesthetics industry, serving markets across Asia-Pacific, Europe, North America, and the Middle East & North Africa. Founded in 2001 and headquartered in Chuncheon-si, South Korea, Hugel recently achieved record net sales, operating profit, and net income in 2024 driven by growth in botulinum toxin, hyaluronic acid fillers, and cosmetics; it entered the US market through a strategic partnership with BENEV Company Inc. for Letybo commercialization following FDA approval, with full-scale sales launched in 2025; expanded into Brazil and Malaysia with Letybo launches and new partner Derma Dream; and strengthened its position as the only South Korean firm approved in the US, China, and Europe botulinum toxin markets.